Germline mutations in the ribonuclease L gene in families showing linkage with HPC1 - UTU Tutkimustietojärjestelmä

A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Germline mutations in the ribonuclease L gene in families showing linkage with HPC1

Tekijät: Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, Faruque M, Moses T, Ewing C, Gillanders E, Hu P, Buinovszky P, Makalowska I, Baffoe-Bonnie A, Faith D, Smith J, Stephan D, Wiley K, Brownstein M, Gildea D, Kelly B, Jenkins R, Hostetter G, Matikainen M, Schleutker J, Klinger K, Connors T, Xiang Y, Wang Z, De Marzo A, Papadopoulos N, Kallioniemi OP, Burk R, Meyers D, Gronberg H, Meltzer P, Silverman R, Bailey-Wilson J, Walsh P, Isaacs W, Trent J

Kustantaja: NATURE AMERICA INC

Julkaisuvuosi: 2002

Journal: Nature Genetics

Tietokannassa oleva lehden nimi: NATURE GENETICS

Lehden akronyymi: NAT GENET

Vuosikerta: 30

Numero: 2

Aloitussivu: 181

Lopetussivu: 184

Sivujen määrä: 4

ISSN: 1061-4036

DOI: https://doi.org/10.1038/ng823

Tiivistelmä

Although prostate cancer is the most common non-cutaneous malignancy diagnosed in men in the United States(1,2), little is known about inherited factors that influence its genetic predisposition(3-5). Here we report that germline mutations in the gene encoding 2'-5'-oligoadenylate(2-5A)-dependent RNase L (RNASEL)(6-8) segregate in prostate cancer families that show linkage to the HPC1 (hereditary prostate cancer 1) region at 1q24-25 (ref. 9). We identified RNASEL by a positional cloning/candidate gene method, and show that a nonsense mutation and a mutation in an initiation codon of RNASEL segregate independently in two HPC1-linked families. inactive RNASEL alleles are present at a low frequency in the general population. RNASEL regulates cell proliferation and apoptosis through the interferon-regulated 2-5A pathway and has been suggested to be a candidate tumor suppressor gene(10-12). We found that microdissected tumors with a germline mutation showed loss of heterozygosity and loss of RNase L protein, and that RNASEL activity was reduced in lymphoblasts from heterozyogous individuals compared with family members who were homozygous with respect to the wildtype allele. Thus, germline mutations in RNASEL may be of diagnostic value, and the 2-5A pathway might provide opportunities for developing therapies for those with prostate cancer.